Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
复制标题
DOI：
10.1016/j.lungcan.2011.06.011
复制
发表时间：
2012-02
期刊：
影响因子：
5.3
通讯作者：
Su, Wu-Chou
中科院分区：
文献类型：
--
作者：
Chen, Helen H. W.;Yan, Jiang-Jou;Chen, Wen-Chung;Kuo, Macus Tien;Lai, Yu-Hsuan;Lai, Wu-Wei;Liu, Hsiao-Sheng;Su, Wu-Chou
最近的研究表明，人铜转运蛋白1（hCtr 1），主要的铜内流转运蛋白，参与铂类抗肿瘤药物的转运。我们研究了hCtr 1和库珀外排转运蛋白ATP 7A和ATP 7 B在接受一线铂类药物化疗的局部晚期非小细胞肺癌（NSCLC）患者中的预测和预后价值。从2004年到2009年，我们确定了54例连续III期NSCLC患者，他们接受了一线铂类药物为基础的双联化疗。对石蜡包埋的治疗前肿瘤样本进行hCtr 1、ATP 7A和ATP 7 B的免疫组织化学研究，并将其与化疗反应和生存率相关联。hCtr 1、ATP 7A和ATP 7 B的过表达分别在68%、48%和74%的参与者中观察到。hCtr 1过表达与更好的化疗反应相关（P < 0.01）;而ATP 7A和ATP 7 B则不然。hCtr 1过表达肿瘤患者的无进展生存期（PFS）和总生存期（OS）较好（分别为P = 0.01和0.047）。在化疗反应和PFS的多因素分析中，只有hCtr 1过表达是一个有利的独立预测和预后因素（均P < 0.01）。这是第一份报告指出，hCtr 1不仅是铂类化疗反应的独立预测因子，而且是III期NSCLC的预后因素。
Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and cooper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P < 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P = 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P < 0.01). This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-09-0311
发表时间：
2009-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Blair BG;Larson CA;Safaei R;Howell SB
通讯作者：
Howell SB
影响因子：
3.6
作者：
Chen, Helen H. W.;Song, Im-Sook;Kuo, Macus Tien
通讯作者：
Kuo, Macus Tien
影响因子：
4.8
作者：
Leonhardt, Karoline;Gebhardt, Rolf;Huster, Dominik
通讯作者：
Huster, Dominik
影响因子：
45.3
作者：
Fossella, F;Pereira, JR;Belani, CP
通讯作者：
Belani, CP
影响因子：
4.8
作者：
Miyashita, H;Nitta, Y;Takebayashi, Y
通讯作者：
Takebayashi, Y